BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34564939)

  • 1. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study.
    Li ZK; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2021 Feb; 32(2):210-214. PubMed ID: 33290314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
    Zhang XY; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
    Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
    Cai M; Zhu J; Zhou G
    Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
    Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
    Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
    Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
    Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
    Yan Q; Yao WT; Du XH; Guo LY; Fan YC
    Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
    [No Abstract]   [Full Text] [Related]  

  • 13. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
    Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
    Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
    Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
    Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
    [No Abstract]   [Full Text] [Related]  

  • 16. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy.
    Li H; Li Y; Song L; Ai Q; Zhang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e314-e319. PubMed ID: 36658675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
    Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
    Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
    Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
    Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.